EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes

Catarina Vale iD, Inês Mariana Lourenço iD, Gabriela Jordan, Ilya Golovaty, Hugo Torres, Tannaz Moin, Martin Buysschaert, João Sérgio Neves iD, Michael Bergman

Diabetes, Obesity and Metabolism · 2025-02 · 27 (2) · 468-481

DOI: 10.1111/dom.16077 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 27.11.2024. Verfasst von Catarina Vale und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Gastric Inhibitory Polypeptide, Drug Therapy, Combination. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 128 Literaturangaben. Gefördert von: National Institutes of Health (NIH) / National Institute of Diabetes and Digestive and Kidney diseases (NIDDK), National Institute of Diabetes and Digestive and Kidney diseases (NIDDK) / Centers for Disease Control and Prevention (CDC), NCCDPHP CDC HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) and glucagon‐Like peptide‐1 receptor agonists (GLP‐1 RA) are recommended in people with type 2 diabetes (T2D) for glycaemic control and for people with high cardiovascular risk. However, current guidelines do not specifically address the role of initial early combination therapy with SGLT2i and GLP‐1 RA or dual gastric inhibitory polypeptide (GIP)/GLP‐1 RA, but rather sequential initiation with either in T2D. This review synthesizes the available evidence on the use of SGLT2i and GLP‐1‐based therapies for T2D and provides a rationale for their combination. The combination of SGLT2i with GLP‐1‐based therapies addresses complementary pathophysiological mechanisms and enhances efficacy in achieving target haemoglobin A1C (HbA1c) levels. SGLT2i and GLP‐1 RA also have been shown to prevent complications of T2D. While both classes reduce adverse cardiorenal events, SGLT2i has a predominant effect on prevention of kidney dysfunction and heart failure, whereas GLP‐1 RA has a more marked effect on the risk of atherosclerotic cardiovascular disease. Both drug classes have favourable safety profiles. Finally, weight loss with combination therapy may have disease‐modifying effects that may reverse T2D progression. We propose that the combination of SGLT2i with GLP‐1 RA or dual GIP/GLP‐1 RA should be considered for most patients with T2D who do not have contraindications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGastric Inhibitory PolypeptideDrug Therapy, CombinationHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsHumansGlycated HemoglobinCardiovascular Diseases

Stichwörter der Autor:innen

GLP‐1 receptor agonistsSGLT2 inhibitorscombination therapydual GIP/GLP‐1 receptor agoniststype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsGastric Inhibitory PolypeptideHypoglycemic AgentsGlycated HemoglobinGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal.
  • Department of Internal Medicine, Centro Hospitalar Universitário de São João, Porto, Portugal.
  • Scripps Health in San Diego, San Diego, California, USA.
  • General Medicine Service, VA Puget Sound Health Care System, Seattle, Washington, USA.
  • Division of General Internal Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
  • David Geffen School of Medicine, University of California, Los Angeles, California, USA.

ORCID-Profile: Catarina Vale, Inês Mariana Lourenço, João Sérgio Neves

Förderung

  • National Institutes of Health (NIH) / National Institute of Diabetes and Digestive and Kidney diseases (NIDDK)
  • National Institute of Diabetes and Digestive and Kidney diseases (NIDDK) / Centers for Disease Control and Prevention (CDC)
  • NCCDPHP CDC HHS
  • University of California, Los Angeles (UCLA)
  • UCOP
  • VA
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • University of California

Zitieren

APA

Vale, C., Lourenço, I. M., Jordan, G., Golovaty, I., Torres, H., Moin, T., Buysschaert, M., Neves, J. S., & Bergman, M. (2025). Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes. Diabetes, Obesity and Metabolism, 27(2), 468-481. https://doi.org/10.1111/dom.16077

Vancouver

Vale C, Lourenço IM, Jordan G, Golovaty I, Torres H, Moin T, et al. Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes. Diabetes, Obesity and Metabolism. 2025;27(2):468-481. doi:10.1111/dom.16077

BibTeX
@article{Vale2025,
  author = {Vale, Catarina and Lourenço, Inês Mariana and Jordan, Gabriela and Golovaty, Ilya and Torres, Hugo and Moin, Tannaz and Buysschaert, Martin and Neves, João Sérgio and Bergman, Michael},
  title = {Early combination therapy with SGLT2i and GLP ‐1 RA or dual GIP / GLP ‐1 RA in type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  volume = {27},
  number = {2},
  pages = {468--481},
  doi = {10.1111/dom.16077}
}
Kostenlos starten →